These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18034606)

  • 1. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps.
    Senstius J; Poulsen C; Hvass A
    Diabetes Technol Ther; 2007 Dec; 9(6):517-21. PubMed ID: 18034606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion.
    Poulsen C; Langkjaer L; Worsøe C
    Diabetes Technol Ther; 2007 Feb; 9(1):26-35. PubMed ID: 17316095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump.
    Senstius J; Harboe E; Westermann H
    Diabetes Technol Ther; 2007 Feb; 9(1):75-9. PubMed ID: 17316101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR; Bell MA; Heyob JA; Storms SM
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
    Mohnicke M; Blecher A; Beichert K; Bidlingmaier B; Todt EJ; Dette C; Rotthaeuser B; Mukherjee B
    J Pharm Sci; 2023 Apr; 112(4):963-973. PubMed ID: 36521561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 14-day in vitro chemical stability of insulin lispro in the MiniMed Paradigm pump.
    Sharrow SD; Glass LC; Dobbins MA
    Diabetes Technol Ther; 2012 Mar; 14(3):264-70. PubMed ID: 22107252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of insulin lispro in insulin infusion systems.
    Lougheed WD; Zinman B; Strack TR; Janis LJ; Weymouth AB; Bernstein EA; Korbas AM; Frank BH
    Diabetes Care; 1997 Jul; 20(7):1061-5. PubMed ID: 9203437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump.
    Senesh G; Bushi D; Neta A; Yodfat O
    J Diabetes Sci Technol; 2010 Jan; 4(1):104-10. PubMed ID: 20167173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model.
    Petersen SB; Nielsen FS; Ribel U; Sturis J; Skyggebjerg O
    J Pharm Pharmacol; 2013 Feb; 65(2):230-5. PubMed ID: 23278690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
    Bode BW
    Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus.
    Petersen SB; Kildegaard J; Nielsen FS; Søndergaard E; Parkner T; Laursen T; Lauritzen T; Skyggebjerg O; Christiansen JS
    Diabetes Obes Metab; 2010 Apr; 12(4):334-40. PubMed ID: 20380654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
    Bott S; Tusek C; Heinemann L; Friberg HH; Heise T
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study.
    Naik S; Kerr D; Begley J; Morton J
    Diabetes Technol Ther; 2012 Nov; 14(11):1018-22. PubMed ID: 23101952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.
    Nosek L; Roggen K; Heinemann L; Gottschalk C; Kaiser M; Arnolds S; Heise T
    Diabetes Obes Metab; 2013 Jan; 15(1):77-83. PubMed ID: 22882249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precipitation of insulin products used for continuous subcutaneous insulin infusion.
    Poulsen C; Langkjaer L; Worsøe C
    Diabetes Technol Ther; 2005 Feb; 7(1):142-50. PubMed ID: 15738712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms.
    Rasmussen CH; Røge RM; Ma Z; Thomsen M; Thorisdottir RL; Chen JW; Mosekilde E; Colding-Jørgensen M
    Eur J Pharm Sci; 2014 Oct; 62():65-75. PubMed ID: 24878388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.